Filing Flows › Charles River Laboratories International (CRL) › Guidance & outlook
Charles River Laboratories International (CRL) guidance and outlook
Charles River Laboratories International (CRL) raised its guidance on Nov 4, 2026: Revenue −0.5% to 0% for FY2026; EPS $8.15–$8.35 for FY2026; EPS $11.35–$11.55 for FY2026. Charles River Laboratories International's 10-Q filed Nov 4, 2026 makes 3 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | +4.7% | new |
| Revenue | FY2026 | −0.5% to 0% | reaffirmed |
| EPS | FY2026 | $8.15–$8.35 | raised |
| EPS | FY2026 | $11.35–$11.55 | raised |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- Over this time, we have built upon our original core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports our clients from target identification through non-clinical development.
- Through the ongoing actions, the Company expects to achieve approximately $300 million of cumulative annualized cost savings by the end of 2026, with more than $175 million realized through fiscal 2025.
- Additionally, we may be required to fund up to $45.0 million of future EBITDA losses and capital expenditures of the divested businesses over a four-year period, which is expected to be fully used by GI.
Charles River Laboratories International's latest quarter
Charles River Laboratories International, Q3 2026: revenue $983M (-2% year over year), operating margin 20.6%, net earnings $333M, operating cash flow $254M. The chart follows the revenue to costs, profit and cash.
Questions
Did Charles River Laboratories International raise or lower its guidance?
Charles River Laboratories International (CRL) raised its guidance on Nov 4, 2026: Revenue −0.5% to 0% for FY2026; EPS $8.15–$8.35 for FY2026; EPS $11.35–$11.55 for FY2026.
What does Charles River Laboratories International expect?
Over this time, we have built upon our original core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports our clients from target identification through non-clinical development. Through the ongoing actions, the Company expects to achieve approximately $300 million of cumulative annualized cost savings by the end of 2026, with more than $175 million realized through fiscal 2025. Additionally, we may be required to fund up to $4
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.